Inhibitors of the mammalian target of rapamycin (mTOR), sirolimus, and everolimus, are strongly associated with an alteration in lipid metabolism, due to their mechanism of action; in fact, mTOR complex-1 [99] is involved in lipoprotein synthesis and insulin resistance. Here, MTOR is linked to Insulin resistance.